Xeris Biopharma Holdings, Inc. (XERS) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-06
(Q2 2026)
— full calendar
Earnings Reports
-
Xeris (XERS) Q1 2026: Recorlev Surges 95%, Fueling Raised Guidance and Pipeline Ambitions
May 07, 2026
-
Xeris (XERS) Q4 2025: Recorlev Patient Base Doubles, Unlocking 44% Revenue Surge
March 02, 2026
-
Xeris (XERS) Q3 2025: Recorlev Patient Growth Surges 108%, Fueling Scalability Push
November 06, 2025
-
Xeris (XERS) Q2 2025: RecorLev Surges 136% as Commercial Portfolio Drives Guidance Hike
August 07, 2025
-
Xeris (XERS) Q1 2025: RecoraLev Revenue Surges 141%, Anchoring 48% Total Growth
July 07, 2025